

Team5 - 2024

2025-02-25

Original Articles

1 - Sepsis-trained macrophages promote antitumoral tissue-resident T cells. Broquet A, Gourrain V, Goronflot T, Le Mabecque V, Sinha D, Ashayeripanah M, Jacqueline C, Martin P, Davieau M, Boutin L, Poulain C, Martin FP, Fourgeux C, Petrier M, Cannevet M, Leclercq T, Guillonneau M, Chaumette T, Laurent T, Harly C, Scotet E, Legentil L, Ferrieres V, Cognac S, Mami-Chouaib F, Mosnier JF, Mauduit N, McWilliam HEG, Villadangos JA, Gourraud PA, Asehnoune K, Poschmann J, Roquilly A. **2024** *Nat Immunol*. PMID [38684922](#)

2 - Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclerose en Plaques) Investigators. **2024** *JAMA Neurol*. PMID [38345791](#)

3 - High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS. Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. **2024** *JAMA Neurol*. PMID [38526462](#)

4 - Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis. Gavaille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Manchon E, Lapergue B, Wiertlewski S, De Seze J, Vukusic S, Laplaud DA; OFSEP Investigators. **2024** *JAMA Neurol*. PMID [38949816](#)

5 - Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction Tissot A, Durand E, Goronflot T, Coiffard B, Renaud-Picard B, Roux A, Demant X, Mornex JF, Falque L, Salpin M, Le Pavec J, Villeneuve T, Boussaud V, Knoop C, Magnan A, Lair D, Berthelot L, Danger R, Brouard S; COLT consortium. **2024** *Respir Res*. PMID [38336710](#)

6 - Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study Boussamet L, Montassier E, Mathe C, Garcia A, Morille J, Shah S, Dugast E, Wiertlewski S, Gourdel M, Bang C, Stürner KH, Masson D, Nicot AB, Vince N, Laplaud DA, Feinstein DL, Berthelot L. **2024** *Sci Rep*. PMID [38565581](#)

7 - Predictive Models of Long-Term Outcome in Patients with Moderate to Severe Traumatic Brain Injury are Biased Toward Mortality Prediction. Martin FP, Goronflot T, Moyer JD, Huet O, Asehnoune K, Cinotti R, Gourraud PA, Roquilly A. **2024** *Neurocrit Care*. PMID [39138720](#)

8 - COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022. Jeantin L, Januel E, Labauge P, Maillart E, de Seze J, Zephir H, Pelletier J, Kerschen P, Biotti D, Heinzlef O, Guilloton L, Bensa C, Theaudin M, Vukusic S, Casez O, Maurousset A, Laplaud D, Berger E, Lebrun-Frenay C, Bourre B, Branger P, Stankoff B, Clavelou P, Thouvenot E, Manchon E, Moreau T, Sellal F, Zedet M, Papeix C, Louapre C. **2024** *Mult Scler*. PMID [38247113](#)

9 - Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study. Marignier R, Laplaud D, Zephir H, Papeix C, Leray E, Amri E, Piotaix M, de Seze J. **2024** *Front Neurol*. PMID [38318238](#)

- 10 - Design, cohort profile and comparison of the KTD-Innov study: a prospective multidimensional biomarker validation study in kidney allograft rejection Goutaudier V, Sablik M, Racape M, Rousseau O, Audry B, Kamar N, Raynaud M, Aubert O, Charreau B, Papuchon E, Danger R, Letertre L, Couzi L, Morelon E, Le Quintrec M, Taupin JL, Vicaut E, Legendre C, Le Mai H, Potluri V, Nguyen TV, Azoury ME, Pinheiro A, Nouadje G, Sonigo P, Anglicheau D, Tieken I, Vogelaar S, Jacquelinet C, Reese P, Gourraud PA, Brouard S, Lefaucheur C, Loupy A; KTD-Innov Consortium. **2024** *Eur J Epidemiol*. PMID [38625480](#)
- 11 - Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort. Dos Santos A, Courtin E, Ruet A, Duffau P, Mathey G, Bekkour I, Ciron J, Michel L, Blanc FX, Aguilar J, Lejeune P, Marc G, Laplaud D, Magot A, Hamidou M, Wiertelwski S. **2024** *Brain Behav*. PMID [39279263](#)
- 12 - Disentangling Multiple Sclerosis heterogeneity in the French territory among genetic and environmental factors via Bayesian heritability analysis. Nova A, Bourguiba-Hachemi S, Vince N, Gourraud PA, Bernardinelli L, Fazia T. **2024** *Mult Scler Relat Disord*. PMID [38880029](#)
- 13 - Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study. Blant JC, De Rossi NN, Gold R, Maurousset A, Kraemer M, Romero-Pinel L, Misu T, Ouallet JC, Pallix Guyot M, Gerevini S, Bakirtzis C, Piñar Morales R, Vlad B, Karypidis P, Moisset X, Derfuss TJ, Jelcic I, Martin-Blondel G, Ayzenberg I, McGraw C, Laplaud DA, Du Pasquier RA, Bernard-Valnet R; for CORPUS and Italian study groups. **2024** *Neurol Neuroimmunol Neuroinflamm*. PMID [38991170](#)
- 14 - Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study. Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, Collongues N, Cohen M, Ayrignac X, Thouvenot E, Zephir H, Bourre B, Froment Tilikete C, Moreau T, Cantagrel P, Kerschen P, Cabasson S, Maubeuge N, Hankiewicz K, Nifle C, Berger E, Megherbi H, Magy L, Klaczynski F, Sarov Riviere M, Giannesini C, Hamelin L, Giroux M, Branger P, Maurousset A, Mathey G, Moulin M, Mele N, Papeix C, Marignier R; as the NOMADMUS study group. **2024** *Neurology*. PMID [38991174](#)
- 15 - Flexibility of a large blindly synthesized avatar database for occupational research: Example from the CON-STANCES cohort for stroke and knee pain. Fadel M, Petot J, Gourraud PA, Descatha A. **2024** *PloS One*. PMID [39083487](#)
- 16 - Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study. Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Seze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frenay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zephir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanche JP, Doghri I, Wahab A, Tchikviladze M, Labeyrie C, Hankiewicz K, Le Page E, Michel L; as the OFSEP Investigators. **2024** *Neurology*. PMID [39321406](#)
- 17 - MRI management for NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS. Durand-Dubief F, Shor N, Audoin B, Bourre B, Cohen M, Kremer S, Maillart E, Papeix C, Ruet A, Savatovsky J, Tourdias T, Ayrignac X, Ciron J, Collongues N, Laplaud D, Michel L, Thouvenot E, Zephir H, Marignier R, Cotton F; NOMADMUS Study Group. **2024** *J Neuroradiol*. PMID [39626832](#)
- 18 - Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France. Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. **2024** *Mult Scler*. PMID [39618051](#)
- 19 - Association between education level and disability progression in patients with multiple sclerosis in France. Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Le Page E, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. **2024** *Mult Scler*. PMID [39614776](#)

Review, Editorial, Comments

- 1 - Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data Demuth S, Ed-Driouch C, Dumas C, Laplaud D, Edan G, Vince N, De Seze J, Gourraud PA. **2024** *Eur J Neurol*. PMID [38860844](#)
- 2 - Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations. Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand

Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zephir H, Marignier R, Audoin B. **2024** *Rev Neurol*. PMID [38969609](#)

3 - Clinical applications of deep learning in neuroinflammatory diseases: A scoping review. Demuth S, Paris J, Faddeenkov I, De Seze J, Gourraud PA. **2024** *Rev Neurol*. PMID [38772806](#)

4 - Donnees synthetiques en medecine : generation, evaluation et limites [Synthetic data in medicine: Generation, evaluation and limits]. Benani A, Vibert J, Demuth S. **2024** *Med Sci*. PMID [39303119](#)